TrialFrontiers in public health2022

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.

Wei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.